Notice of Partial Forfeiture (Decrease in the Number of Shares to be Issued, etc.) in Connection with the Issuance of New Shares Under the RSU Plan

Notice of Partial Forfeiture (Decrease in the Number of Shares to be Issued, etc.) in Connection with the Issuance of New Shares Under the RSU Plan

1. Changes to the Outline of the Issuance of New Shares Under Nos. 18 and 20 RSU Plan (Changes are underlined)

   		After Change	Before Change
   (i)	Payment date	RSU No. 18: 18 May 2026 RSU No. 20: 18 May 2026	RSU No. 18: 18 May 2026 RSU No. 20: 18 May 2026
   (ii)	Type and number of shares to be issued	729,558 shares of the Company's common stock (Breakdown) RSU No. 18: 208,483 shares RSU No. 20: 521,075 shares	736,190 shares of the Company's common stock (Breakdown) RSU No. 18: 208,977 shares RSU No. 20: 527,213 shares
   (iii)	Payment amount	RSU No. 18: 1,011 Yen per share RSU No. 20: 1,011 Yen per share	RSU No. 18: 1,011 Yen per share RSU No. 20: 1,011 Yen per share
   (iv)	Total amount of payment	RSU No.18: 210,776,313 Yen RSU No.20: 526,806,825 Yen	RSU No.18: 211,275,747 Yen RSU No.20: 533,012,343 Yen
   (v)	Allottees	RSU No. 18: subsidiaries RSU No. 20: subsidiaries	RSU No. 18: subsidiaries RSU No. 20: subsidiaries
   (vi)	Other details	The Securities Registration Statements relating to the issuance of new shares under RSU Award Nos. 18 and 20 have been filed in accordance with the Financial Instruments and Exchange Act.	The Securities Registration Statements relating to the issuance of new shares under RSU Award Nos. 18 and 20 have been filed in accordance with the Financial Instruments and Exchange Act.

   1. Directors and Executive Officers in total 143 Directors of subsidiaries and employees of the Company and its

   2. Directors and Executive Officers in total 203 Directors of subsidiaries and employees of the Company and its

   1. Directors and Executive Officers in total 145 Directors of subsidiaries and employees of the Company and its

   2. Directors and Executive Officers in total 205 Directors of subsidiaries and employees of the Company and its

2. Reason for the Change

The changes to the number of allottees, the number of shares to be issued, and the total issue price are due to the forfeiture by total four (4) persons among those who had been scheduled to be allotted shares at the time the issuance of new shares was resolved.

-END-

Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit https://www.nxera.life

LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life

Mark Swallow, Frazer Hall, Erica Hollingsworth

+44 (0)203 928 6900 | Nxera@medistrava.com

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

2 of 2